MX2016007352A - Inhibidores de serina/treonina cinasa. - Google Patents

Inhibidores de serina/treonina cinasa.

Info

Publication number
MX2016007352A
MX2016007352A MX2016007352A MX2016007352A MX2016007352A MX 2016007352 A MX2016007352 A MX 2016007352A MX 2016007352 A MX2016007352 A MX 2016007352A MX 2016007352 A MX2016007352 A MX 2016007352A MX 2016007352 A MX2016007352 A MX 2016007352A
Authority
MX
Mexico
Prior art keywords
serine
kinase inhibitors
threonine kinase
inhibitors
compositions
Prior art date
Application number
MX2016007352A
Other languages
English (en)
Other versions
MX368443B (es
Inventor
Steven Do
Aleksandr Kolesnikov
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016007352A publication Critical patent/MX2016007352A/es
Publication of MX368443B publication Critical patent/MX368443B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a compuestos que tienen la fórmula I en donde R1, X1, X2, X3 y X4 como se define en la presente son inhibidores de la cinasa ERK. También se describen composiciones y métodos para tratar trastornos hiperproliferativos. (ver Fórmula).
MX2016007352A 2013-12-06 2014-12-03 Inhibidores de serina/treonina cinasa. MX368443B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912905P 2013-12-06 2013-12-06
PCT/US2014/068452 WO2015085007A1 (en) 2013-12-06 2014-12-03 Serine/threonine kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2016007352A true MX2016007352A (es) 2016-09-08
MX368443B MX368443B (es) 2019-10-02

Family

ID=52350292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007352A MX368443B (es) 2013-12-06 2014-12-03 Inhibidores de serina/treonina cinasa.

Country Status (23)

Country Link
US (5) US9867833B2 (es)
EP (1) EP3077401B1 (es)
JP (2) JP6449293B2 (es)
KR (1) KR102359759B1 (es)
CN (1) CN106029672B (es)
AR (1) AR098647A1 (es)
AU (1) AU2014360455B2 (es)
BR (1) BR112016012844B1 (es)
CA (1) CA2932729C (es)
CL (1) CL2016001368A1 (es)
CR (1) CR20160309A (es)
EA (1) EA031243B1 (es)
IL (1) IL246017B (es)
MA (1) MA39170B1 (es)
MX (1) MX368443B (es)
MY (1) MY176049A (es)
PE (1) PE20160886A1 (es)
PH (1) PH12016501071B1 (es)
SG (1) SG11201604573WA (es)
TW (1) TWI557126B (es)
UA (1) UA120506C2 (es)
WO (1) WO2015085007A1 (es)
ZA (1) ZA201604461B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015114936A (ru) 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
WO2015103137A1 (en) * 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
CA2934679C (en) 2013-12-30 2023-02-28 Genentech, Inc. Serine/threonine kinase inhibitors
TN2018000119A1 (en) 2015-11-09 2019-10-04 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TWI827550B (zh) 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
JP7433898B2 (ja) 2019-12-26 2024-02-20 キヤノン株式会社 光電変換素子、光電変換システム

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438027A1 (en) * 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
KR20080052665A (ko) 2005-09-15 2008-06-11 페인셉터 파마 코포레이션 뉴로트로핀 매개 활성 조절 방법
WO2008078100A2 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
EP2002836B1 (en) 2007-05-31 2010-10-20 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
MX339873B (es) 2011-02-28 2016-06-15 Genentech Inc Inhibidores de serina/treonina cinasa.
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
ES2857649T3 (es) 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
EP2888247B1 (en) 2012-08-27 2020-03-25 Array Biopharma, Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative diseases
RU2015114936A (ru) 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
CA2934679C (en) 2013-12-30 2023-02-28 Genentech, Inc. Serine/threonine kinase inhibitors
ES2733495T3 (es) 2014-04-09 2019-11-29 Genentech Inc Proceso para la fabricación de medicamentos

Also Published As

Publication number Publication date
CA2932729C (en) 2021-02-23
US20180000833A1 (en) 2018-01-04
PE20160886A1 (es) 2016-09-14
AR098647A1 (es) 2016-06-01
US10842799B2 (en) 2020-11-24
EA031243B1 (ru) 2018-12-28
PH12016501071A1 (en) 2016-07-25
EP3077401A1 (en) 2016-10-12
CL2016001368A1 (es) 2016-12-09
JP2016539153A (ja) 2016-12-15
CR20160309A (es) 2016-08-25
CA2932729A1 (en) 2015-06-11
EA201691177A1 (ru) 2016-10-31
EP3077401B1 (en) 2018-04-18
CN106029672A (zh) 2016-10-12
US11376260B2 (en) 2022-07-05
SG11201604573WA (en) 2016-07-28
BR112016012844A2 (es) 2017-08-08
KR20160093703A (ko) 2016-08-08
ZA201604461B (en) 2022-05-25
WO2015085007A1 (en) 2015-06-11
IL246017B (en) 2019-10-31
US20150182537A1 (en) 2015-07-02
US10517878B2 (en) 2019-12-31
TW201522338A (zh) 2015-06-16
AU2014360455B2 (en) 2018-05-10
KR102359759B1 (ko) 2022-02-09
US9867833B2 (en) 2018-01-16
TWI557126B (zh) 2016-11-11
PH12016501071B1 (en) 2016-07-25
MA39170A1 (fr) 2018-04-30
IL246017A0 (en) 2016-08-02
US10278975B2 (en) 2019-05-07
JP2019034970A (ja) 2019-03-07
BR112016012844B1 (pt) 2023-01-10
UA120506C2 (uk) 2019-12-26
US20210106593A1 (en) 2021-04-15
AU2014360455A1 (en) 2016-07-07
MY176049A (en) 2020-07-22
US20190192534A1 (en) 2019-06-27
MA39170B1 (fr) 2019-05-31
US20200078371A1 (en) 2020-03-12
NZ721361A (en) 2021-07-30
JP6449293B2 (ja) 2019-01-09
CN106029672B (zh) 2019-03-29
MX368443B (es) 2019-10-02

Similar Documents

Publication Publication Date Title
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12016501071A1 (en) Serine/threonine kinase inhibitors
PH12015501660A1 (en) Erk inhibitors and uses thereof
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12016501388A1 (en) Heteroaryls and uses thereof
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2018006148A (es) Inhibidores de cxcr2.
MX2016007898A (es) Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos.
BR112013021896A2 (pt) inibidores de serina/treonina cinase
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX371356B (es) Profarmacos de aminoquinazolina inhibidora de cinasa.
NZ711192A (en) Process for making benzoxazepin compounds
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MA39824A (fr) Composés azole amido-substitués
ZA201604932B (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
TWI562990B (en) Novel compounds as inhibitors of janus kinase

Legal Events

Date Code Title Description
FG Grant or registration